<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04591392</url>
  </required_header>
  <id_info>
    <org_study_id>008-022</org_study_id>
    <nct_id>NCT04591392</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of reSept ASD Occluder for Treating Secundum ASD</brief_title>
  <acronym>ASCENT ASD</acronym>
  <official_title>Evaluation of the Safety and Efficacy of the reSept ASD Occluder to Treat Patients With Clinically Significant Secundum Atrial Septal Defect</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>atHeart Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>atHeart Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and efficacy of the reSept ASD Occluder to treat patients with&#xD;
      clinically significant secundum atrial septal defect&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, three-stage, single arm, multi-site, clinical investigation evaluating the&#xD;
      safety and efficacy of the reSept ASD Occluder in treating clinically significant secundum&#xD;
      ASD. Outcomes/endpoints of the clinical investigation will be compared with established&#xD;
      performance goals for FDA approved transcatheter secundum ASD occluders.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">September 2027</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with 12-Month Composite Clinical Success</measure>
    <time_frame>12 months</time_frame>
    <description>Clinically effective ASD closure, defined as no residual ASD or clinically insignificant residual ASD as determined by core laboratory review; and&#xD;
No re-intervention to treat the defect; and&#xD;
No device or procedure related serious adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with CEC adjudicated Device- or Procedure-related SAEs</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of subjects experiencing one or more serious device- or procedure related adverse events through the 12 month follow up visit, as adjudicated by the Clinical Events Committee (CEC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ASD Closure Success among Technical Success Subjects</measure>
    <time_frame>1 month, 6 months and 12 months</time_frame>
    <description>Assessment of device performance will include closure success, among subjects that were technical successes (i.e. successful placement and release of the reSept ASD Occluder at the ASD), defined as no residual ASD or clinically insignificant residual ASD determined by echocardiography. Assessment of closure success at each follow up through the 12-month follow up will be assessed by TTE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects with Device- or Procedure-related AEs</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of subjects experiencing one or more non serious device- or procedure-related adverse events through the 12-month follow up visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heart Septal Defect</condition>
  <condition>Heart Septal Defects, Atrial</condition>
  <condition>Heart Defects, Congenital</condition>
  <condition>Cardiovascular Abnormalities</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Congenital Abnormalities</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASD closure with the reSept ASD Occluder</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>reSept ASD Occluder</intervention_name>
    <description>Transcatheter closure of secundum ASD using a permanent implant</description>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All responses must be Yes to be eligible:&#xD;
&#xD;
          1. Age &lt; 85 years.&#xD;
&#xD;
          2. Body weight â‰¥ 15 kg / 33 lb.&#xD;
&#xD;
          3. Males and Females.&#xD;
&#xD;
          4. Clinically significant, isolated secundum ASD associated with a L-R shunt and signs of&#xD;
             RV volume overload that, based upon the expertise of attending physicians requires&#xD;
             treatment.&#xD;
&#xD;
          5. ASD of size 4 to 19 mm on screening diagnostic echocardiogram.&#xD;
&#xD;
          6. Isolated secundum ASD of size 4 to 22 mm on stop flow balloon diameter, based upon&#xD;
             echocardiographic and fluoroscopic evidence obtained at procedure.&#xD;
&#xD;
          7. Able to take required medications: ASA (Aspirin), low dose (75-100 mg/day), 24 hours&#xD;
             prior to and for 6 months following the procedure; Heparin intra-procedurally.&#xD;
&#xD;
          8. Adequate septal rim/defect margins to support the device. The rim is considered&#xD;
             adequate unless it measures less than 5mm over an entire 45 degree segment.&#xD;
&#xD;
          9. Capable of giving informed consent, or, for minors, consent of the parent or legal&#xD;
             guardian, and willing to comply with the clinical investigation requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        All responses must be No to be eligible:&#xD;
&#xD;
          1. Pregnancy. Females with child-bearing potential are required to be tested for&#xD;
             pregnancy prior to treatment, in accordance with the local institution's policy. For&#xD;
             minor females, a pregnancy test will be done in accordance with the local&#xD;
             institution's policy.&#xD;
&#xD;
          2. Any significant valve dysfunction that contraindicates ASD closure, or increased&#xD;
             pulmonary vascular resistance/severe pulmonary hypertension.&#xD;
&#xD;
          3. Acquired pathological or congenital abnormalities of the cardiovascular system (other&#xD;
             than isolated secundum ASD; e.g. congenital malformations, calcification, myocardial&#xD;
             infarction, intracardiac thrombi, dilated cardiomyopathy, untreated coronary disease&#xD;
             or CAD treated with a stent in the prior 12 months) being clinically significant, that&#xD;
             would interfere with the conduct of the clinical investigation.&#xD;
&#xD;
          4. Subjects having undergone left sided structural heart interventions performed via&#xD;
             transseptal access (e.g. Mitraclip, LAAO, percutaneous mitral valve replacement).&#xD;
&#xD;
          5. Evidence of thrombus in the left atrium, left atrial appendage, other cardiac chamber,&#xD;
             or the inferior vena cava.&#xD;
&#xD;
          6. Sepsis or any other infection that was not successfully treated at least 30 days prior&#xD;
             to device placement.&#xD;
&#xD;
          7. Active endocarditis or other infection(s) producing bacteremia.&#xD;
&#xD;
          8. History of atrial tachycardia, atrial fibrillation or flutter, AV block, or&#xD;
             ventricular arrhythmia requiring antiarrhythmic medication, pacemaker or AICD.&#xD;
&#xD;
          9. Vasculature is of inadequate size to accommodate all procedural instrumentation.&#xD;
&#xD;
         10. Known allergy to investigational device components or medications, or other&#xD;
             contraindication to clinical investigation medications (acetylsalicylic acid,&#xD;
             heparin), including a documented history of bleeding, clotting or coagulation&#xD;
             disorders, untreated ulcer or any other contraindications to acetylsalicylic acid or&#xD;
             antiplatelet therapy.&#xD;
&#xD;
         11. Known hypercoagulable state.&#xD;
&#xD;
         12. Any disorder in the investigator's opinion that could interfere with compliance of&#xD;
             safety evaluation as well as any severe concurrent illness that would limit life&#xD;
             expectancy (e.g. malignancies).&#xD;
&#xD;
         13. Currently an active subject in an investigational drug or device study that could&#xD;
             confound the results of this study.&#xD;
&#xD;
         14. Patients who, in the opinion of the investigator, are inappropriate for inclusion into&#xD;
             this clinical investigation or will not comply with requirements of the clinical&#xD;
             investigation.&#xD;
&#xD;
         15. Are known to abuse drugs or alcohol.&#xD;
&#xD;
         16. Patients with the diagnosis of Patent Foramen Ovale (PFO).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Latson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joe DiMaggio Children's Hospital/Memorial Healthcare</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Saibal Kar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Los Robles Regional Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandi Sadowski</last_name>
    <phone>+1 408-412-7245</phone>
    <email>b.sadowski@atheartmedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Los Robles Regional Medical Center</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mane Arabyan</last_name>
      <email>Mane.Arabyan@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Saibal Kar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Joe DiMaggio Children's Hospital/Memorial Healthcare System</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doris Alaby, RN, BSN</last_name>
      <email>DAlaby@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Larry Latson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blake Armstrong</last_name>
      <email>blar@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Zampi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Sullivan, MS</last_name>
      <email>nsulliva@med.wayne.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Forbes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Raviv</last_name>
      <email>jessica.raviv@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Barry Love, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Edwards, PhD</last_name>
      <email>sme2146@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Sommer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivia Martino</last_name>
      <email>martinoo@chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Triguba</last_name>
      <email>trigubam@chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew Gillespie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Madison Johnson</last_name>
      <email>johme@musc.edu</email>
    </contact>
    <investigator>
      <last_name>John Rhodes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Bryceland, RN</last_name>
      <email>lgs2m@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth McKinney</last_name>
      <email>Liz.McKinney@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Heart Septal Defects</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Cardiovascular Abnormalities</mesh_term>
    <mesh_term>Heart Septal Defects, Atrial</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

